Sign in
Taking peoplePhase 2

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Key facts

Who runs it
University of Oxford
Where
Brazil, Laos, Nepal, and Thailand4 sites in 4 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
3,000 people, planned
Started
22 Feb 2023
Expected to end
1 Jan 2027
Type of study
Interventional, 11 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Oseltamivir
  • Favipiravir
  • Zanamivir
  • Baloxavir
  • Molnupiravir
  • Peramivir
  • Laninamivir
  • Oseltamivir and Baloxavir
  • Oseltamivir and Favipiravir
  • Favipiravir and Baloxavir
Record updated
14 April 2026

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Patient understands the procedures and requirements and is willing and able to give informed consent for full participation in the study
  • Adults, male or female, aged 18 to 60 years at time of consent
  • Early symptomatic Influenza (A or B); at least one reported symptom of influenza (including fever, history of fever, myalgias, headache, cough, fatigue, nasal congestion, rhinorrhoea and sore throat) within 4 days (96 hours)
  • Influenza positive by rapid antigen test OR a positive RT-PCR test for influenza viruses within the last 24hrs with a Ct value of <30
  • Able to walk unaided and unimpeded in activities of daily living (ADLs)
  • Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits

Who cannot take part

  • Taking any concomitant medications or drugs which could interact with the study medications or have antiviral activity
  • Received live attenuated influenza virus vaccine within 3 weeks prior to study entry
  • Presence of any chronic illness/condition requiring long term treatment or other significant comorbidity
  • Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics
  • Currently participating in another interventional influenza or COVID-19 therapeutic trial
  • Known to be currently co-infected with SARS-CoV-2 (i.e. confirmed with positive ATK or RT-PCR)
  • Clinically relevant laboratory abnormalities discovered at screening; Haemoglobin <10g/dL; Platelet count <100,000/uL; ALT > 2x ULN; Total bilirubin >1.5 x ULN; eGFR <70mls/min/1.73m2
  • The patient may not enter the study if ANY of the following apply:
  • BMI ≥35 Kg/m2
  • For females: pregnancy, actively trying to become pregnant or lactation (healthy women on OCP are eligible to join)
  • Clinical evidence of pneumonia- e.g. shortness of breath, hypoxaemia, crepitations (imaging not required)

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Influenza

This trial is currently available in Brazil, Laos, Nepal, and Thailand.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential, adaptive, platform trial, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no treatment) and each other.

Read full original descriptionShow less

AD ASTRA study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator

The 11 groups in the trial

  • Oseltamivir (TAMIFLU®)Treatment being tested

    Treatment: Oseltamivir

  • FavipiravirTreatment being tested
  • Zanamivir (RELENZA®) [Pending addition]Treatment being tested

    Treatment: Zanamivir

  • Baloxavir (XOFLUZA®)Treatment being tested

    Treatment: Baloxavir

  • Molnupiravir [Pending addition]Treatment being tested

    Treatment: Molnupiravir

  • Peramivir (RAPIVAB®) [Pending addition]Treatment being tested

    Treatment: Peramivir

  • Laninamivir (INAVIR®) [Pending addition]Treatment being tested

    Treatment: Laninamivir

  • Oseltamivir and Baloxavir [Pending addition]Treatment being tested

    Treatment: Oseltamivir and Baloxavir

  • Oseltamivir and Favipiravir [Pending addition]Treatment being tested

    Treatment: Oseltamivir and Favipiravir

  • Favipiravir and Baloxavir [Pending addition]Treatment being tested

    Treatment: Favipiravir and Baloxavir

  • Negative control groupNo study treatment, for comparison

    No treatment (except antipyretics- paracetamol)

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA)
Criteria questions
Built from NCT05648448, who can take part
Publications
Record updated
14 April 2026